Spotlight
Obituaries
Classifieds
Families First
VCAs Best of Guide
News
Weather
Specialists
Sports
Business
Consumer
Health
Life
Out & About
Login
Recommended
WRAL Severe Weather team forecasts 'near-average' number of tropical systems in 2025
Recommended
North Carolina cracks down on unlicensed massage practices in state shopping malls
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptose Biosciences Inc
(OP:
APTOF
)
1.680
UNCHANGED
Streaming Delayed Price
Updated: 2:39 PM EDT, May 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptose Biosciences Inc
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
May 20, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
May 14, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports First Quarter 2025 Results
May 08, 2025
Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline Therapy
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.